Argenx Se · EURONEXT:ARGX
Argenx — Investor Presentation (March 2025)
29 slides from Argenx's investor presentation, March 2025
Slide 1: Reaching Patients Through Immunology Innovation
Reaching Patients Through Immunology Innovation C o r p o r a t e P r e s e n t a t i o n M a r c h 2 0 2 5
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Innovation has no value unless it provides meaningful benefit to patients
Innovation has no value unless it provides meaningful benefit to patients 3
Slide 4: VYVGART Builds Foundation of Innovation
VYVGART® Builds Foundation of Innovation Foundational First-in-Class Pipeline in a Immune Target Potential Best-in-Class Product Opportunity FcRn Fc Fragment VYVGART Approved 3 Indications 15 In Development Precision IgG ABDEG Expansive Development Degradation Portfolio 4
Slide 5: VYVGART is Setting a New Standard for Patients
VYVGART is Setting a New Standard for Patients MG CIDP 8/10 Response rate1 MG-ADL SCORE ≤ 5 7/10 Meaningful response2 ECI STAGE A % No/minimal % Substantial 34 improvement in 54 symptoms1 MSE = MG-ADL SCORE of 0 or 1 functional ability2 ≥2 POINT DECREASE IN INCAT Fred, MG Patient Jamilah, CIDP Patie
Slide 6: Financial Strength to Invest in Sustainable Innovation
Financial Strength to Invest in Sustainable Innovation Product Net Sales by Quarter 2024 Product Net Sales 750 737 700 650 $2.2B 600 573 550 500 478 Strong Cash Position 450 $M 400 350 329 374 398 $3.4B 300 Cash reflects cash, cash equivalents and current financial assets as of December 31, 2024 269
Slide 7: 2025 Strategic Priorities
2025 Strategic Priorities Reach more patients Expand next wave with VYVGART Fuel pipeline growth of innovation 10 Phase 3s 4 New PFS Launch Molecules in 10 Phase 2s Phase 1 7
Slide 8: Reach More Patients with VYVGART
Reach More Patients with VYVGART 8
Slide 9: PFS to Accelerate VYVGART Growth in MG and CIDP
PFS to Accelerate VYVGART Growth in MG and CIDP Aiming for Self- Pre-Filled Syringe* Administration *FPO Application Pending Not FDA Approved PFS PDUFA Autoinjector* 4 Global April 10, 2025 Decisions on Autoinjector Approval in 2025 *FPO 2027 Planned Launch Not FDA Approved 9
Slide 10: Growing VYVGART Leadership in MG
Growing VYVGART Leadership in MG Path to 60K Addressable Patients U.S. Addressable MG Patients +25K #1 BRANDED +7K BIOLOGIC +11K Growth in 60K Biologics for gMG Share of Market Ocular 17K Consistent QoQ growth Seronegative VYVGART has set a high bar Addressable Total Addressable Market at Launch Mar
Slide 11: Opportunity To Set New Standard in Ocular MG
Opportunity To Set New Standard in Ocular MG Ocular Domain Effect in ADAPT (1) Addressing Unmet Need High Disease Burden Impaired ability to work, drive and participate in social activities MG-ADL ocular subdomain %change from baseline in High Treatment Burden Frequent chronic, high doses of oral co
Slide 12: Continued Momentum in CIDP
Continued Momentum in CIDP Patients ~1,000 Patients 25% New on Therapy Prescribers Majority IVIg-experienced Breadth and depth of prescribers Physicians 90% Lives Covered Global Expansion Majority policies favorable Multiple planned launches in 2025 Payors 12
Slide 13: Reaching Patients Across the Globe
Reaching Patients Across the Globe DECISIONS PENDING FOR 2025 US EU • CIDP launched with >1,000 • Reimbursement complete in 13 countries • CHMP recommendation for PFS in gMG gMG patients on treatment as of end Saudi Arabia of 4Q Japan • CIDP launched with positive early feedback DECISIONS PENDING FO
Slide 14: Fuel Pipeline Growth
Fuel Pipeline Growth argenx?
Slide 15: Our Pipeline is Positioned to Fuel Continuous Growth
Neuromuscular Our Pipeline is GBS MG Positioned to Fuel Crisis NMOSD Rheumatology MG Continuous Growth Steroid Taper oMG IMNM SJD snMG AIE MMN SSC Bubble Size and Color Indicates CIDP CIDP DM ASyS Prevalence Lead gMG SMA Expand CMS ITP DM ALS <15k 15-100k 100-300k Investigate/ESR DGF LN TED Asset IT
Slide 16: Empasiprubart is Now a Phase 3 Asset
Empasiprubart is Now a Phase 3 Asset Foundational First-in-Class Pipeline in a Immune Target Potential Best-in-Class Product Opportunity Complement C2-Specific Empasiprubart Factor C2 Antibody IgG IgM Mannose sugar CP LP MMN and CIDP C4 C2 Registrational Studies C3 C5 DGF and DM Proof of Concept Stu
Slide 17: Phase 2 ARDA Study: Transformational Data in MMN
Phase 2 ARDA Study: Transformational Data in MMN Empasiprubart Treated Patients Feel Significant Unmet Need Study Met Primary Endpoint Better than their Best on IVIg Life-Limiting Symptoms Empasiprubart reduced risk Cohort 1: 94.4% improved of IVIg retreatment by up to 100 91% Percentage of Particip
Slide 18: Disrupting Blockbuster Markets
Disrupting Blockbuster Markets Two Head-to-Head Phase 3 Studies with IVIg Innovation Builds Markets Following similar analogues in MG and MS MMN EMPASSION Study Ongoing More innovation brings better >400 patients enrolled in iMMersioN outcomes for more natural history study patients CIDP Future EMVI
Slide 19: ARGX-119 is Now in Proof-of-Concept Studies
ARGX-119 is Now in Proof-of-Concept Studies Foundational First-in-Class Pipeline in a Immune Target Potential Best-in-Class Product Opportunity MuSK MuSK Agonist ARGX-119 Antibody CMS and ALS Proof-of-concept Studies MuSK SMA P P Next Indication Crucial for Neuromuscular SIMPLE Junction Function Ant
Slide 20: Expand Next Wave of Innovation
Expand Next Wave of Innovation 20
Slide 21: 4 Phase 1 Molecules in 2025
4 Phase 1 Molecules in 2025 Continued Leadership with Broad Immune System Targets ARGX-213 ARGX-121 ARGX-109 ARGX-220 FcRn IgA IL-6 Target Undisclosed Fc-ABDEGTM Fc-ABDEGTM NHance® α-albumin VHH Prolonged IgG reduction Rapid, deep IgA reduction Best-in-class potency First-in-class sweeper Potential
Slide 22: Innovation Model Generating World-Class Pipeline
Innovation Model Generating World-Class Pipeline Active IIP Programs 4 PHASE 1 10 Proof of Concept 10 PHASE 3 APPROVED Neuro Target Neuro Target ARGX-213 (FcRn) Lupus Nephritis Seronegative MG Neuro Target Neuro Target ARGX-109 (IL6) AMR Ocular MG Neuro Target Rheum Target ARGX-121 (IgA) Scleroderma
Slide 23: Significant Momentum Ahead
Significant Momentum Ahead 1H25 PFS FDA, EMA decisions on approval Regional PFS Approvals 4 PFS Canada, Japan decisions on approval Efgartigimod IVIg Switch CIDP Ph4 Efgartigimod Seronegative MG Ph3 DECISIONS ON APPROVAL 2H25 Efgartigimod Lupus Nephritis Ph2 Empasiprubart DGF Ph2 6 ARGX-119 CMS Ph1b
Slide 24: Strong Growth Trajectory to 50K Patients
Strong Growth Trajectory to 50K Patients 50K CMS DM CIDP Sjogren’s Myositis TED MMN oMG snMG CIDP ITP gMG Wave 1: TODAY Wave 2 (2026-2027) Wave 3 (2028-2030) VYVGART Empasiprubart ARGX-119 24
Slide 25: Vision 2030
Vision 2030 COMMITMENT TO OUR INNOVATION MISSION 5 New Molecules in Phase 3 10 Labeled Indications 50k Patients on Treatment 25
Slide 26: Appendix
Appendix argenx?
Slide 27: Product Net Sales: Q4 of $737 million
Product Net Sales: Q4 of $737 million Product Net Sales by Quarter Q4 2024: growth of 98% vs Q4 2023 (in millions of $) Q4 2024 Q4 2023 Growth % * 800 737 US 649 326 99% 700 Japan 27 17 66% $’m RoW 49 24 105% 600 573 China supply 12 7 65% 500 478 Total 737 374 98% 398 400 374 329 300 269 218 Q4 2024
Slide 28: Q4 2024 Financial Summary
Q4 2024 Financial Summary Summary P/L Three months ended Twelve months ended Cash* December 31 December 31 in million of $ 2024 2023 2024 2023 $1.5 billion in cash and cash equivalents and $1.9 billion in current financial assets Product net sales 737 374 2,186 1,191 Collaboration revenue 1 32 4 36
Slide 29: Next Wave of Growth for VYVGART
Next Wave of Growth for VYVGART Sjogren’s Disease Myositis (IMNM, ASyS, DM) Thyroid Eye Disease • IGF-1R, TSHR AutoAbs BIOLOGY • Anti-Ro/Anti-La AutoAbs • Myositis AutoAbs • Pathogenic potential of IgG (in vitro and in vivo) • Passive transfer model evidence • Passive transfer model evidence (IMNM)